Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07103642 · ClinicalTrials.gov registry record
EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)
A clinical trial of Pulmonary Disease, Chronic Obstructive, sponsored by AstraZeneca.
- Completed
- Registry status
- 3,402
- Enrollment target
- 1
- Study location
NCT07103642: Completed study of Pulmonary Disease, Chronic Obstructive, sponsored by AstraZeneca.
NCT07103642 is a study of Pulmonary Disease, Chronic Obstructive that has completed, run by AstraZeneca. The registered enrollment target is 3,402 participants, above the 998-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (241% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07103642, a study of Pulmonary Disease, Chronic Obstructive, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- 3,402 participants
- Enrollment target
- 1
- Study location
Study Summary
A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe cardiopulmonary events and other real-world outcomes in Japan
Primary Outcome
Annualized rates of COPD exacerbation events observed from index date (qualifying exacerbation event) through study completion (or until end of data availability with a median follow-up of 713 days
Conditions Studied
Interventions
- DRUG BGF
Study Locations (1)
Delaware
- AstraZeneca - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3,402 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2024-10-18 |
What the finished NCT07103642 record still lists
NCT07103642 is an observational study that tracks outcomes without assigning an intervention. Its 3,402 participants enrollment target places it among the larger protocols in the corpus, above the 998-participant average among 74 other Pulmonary Disease, Chronic Obstructive trials with a reported enrollment target (241% higher).
The record links to 1 condition, with Pulmonary Disease, Chronic Obstructive appearing as the primary indexed condition, and to 1 intervention - of which BGF is the first listed.
NCT07103642 reports a single indexed study location in Delaware.
Frequently Asked Questions
What is clinical trial NCT07103642 about?
NCT07103642 is a clinical study titled "EXACERBATIONS AND REAL-WORLD OUTOMES AMONG PATIENTS WITH COPD INITIATING BREZTRI (EROS+CP Japan Study)". A retrospective real-world data study, assessing the relationship between the timing of Budesonide/Glycopyrrolate/Formoterol initiation following an exacerbation and the occurrence of subsequent exacerbations, severe cardiopulmonary events and other real-world outcomes in Japan
What is the current status of trial NCT07103642?
This trial is currently completed. The enrollment target is 3,402 participants. The study started on 2024-08-15. Estimated completion is 2024-10-18.
What conditions does trial NCT07103642 study?
This clinical trial studies the following conditions: Pulmonary Disease, Chronic Obstructive.
What interventions are being tested in trial NCT07103642?
The interventions under investigation include: BGF (DRUG).
Who is sponsoring clinical trial NCT07103642?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07103642 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Disease, Chronic Obstructive
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07103642's enrollment target sits among peer trials
3,402 7th of 74 higher than 68 of 74 other Pulmonary Disease, Chronic Obstructive trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Disease, Chronic Obstructive trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)
RECRUITING · Phase 3
-
A Study for GSK3862995B in Healthy Participants and Participants With Chronic Obstructive Pulmonary Disease
RECRUITING · Phase 1
-
Pragmatic Trial to Enhance Quality Safety, and Patient Experience in COPD
RECRUITING · NA
-
eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation
RECRUITING · Phase 3
-
Trial to Determine Effective Aspirin Dose in COPD
RECRUITING · Phase 3
-
Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)
RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03474029 · 3,400 participants · Phase 2
Assessment of the Safety, Tolerability, and Effectiveness of Rifapentine Given Daily for LTBI
- NCT07142954 · 3,400 participants · Phase 3
Epidemiology and Biomarker Study in Alzheimer's Disease
- NCT06880055 · 3,375 participants
Shield Post-Approval Study Protocol
- NCT03674307 · 3,306 participants · NA
Screening for Asymptomatic Coronary Artery Disease in Kidney Transplant Candidates
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI